S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Perceptive Advisors/Q2 2024

Perceptive Advisors

Period: Q2 2024 Β· Filed: 2024-08-16
View on SEC EDGAR β†—
AUM
$4.15B
Total portfolio value
Positions
110
Reported securities
Top Holding
CERE
10.6% $441.4M
QoQ Changes
+0 / -0
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2024-08-16) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
CERECEREVEL THERAPEUTICS HLDNG I$441.4M10.63%β€”β€”
10.6%
FOLDAMICUS THERAPEUTICS INC$278.3M6.70%β€”β€”
6.7%
ACLXARCELLX INC$214.7M5.17%$53.60β€”
5.2%
IOVAIOVANCE BIOTHERAPEUTICS INC$208.0M5.01%$8.06$4.31-46.5%
5.0%
NUVLNUVALENT INC$193.4M4.66%$75.51$123.73+63.9%
4.7%
RYTMRHYTHM PHARMACEUTICALS INC$141.5M3.41%$42.67$114.17+167.6%
3.4%
PCVXVAXCYTE INC$140.7M3.39%$76.94$58.39-24.1%
3.4%
SLNOSOLENO THERAPEUTICS INC$130.8M3.15%$42.29β€”
3.1%
ITCIINTRA-CELLULAR THERAPIES INC$117.6M2.83%β€”β€”
2.8%
IMTXIMMATICS N.V$94.0M2.26%$12.00$9.95-17.1%
2.3%
NBIXNEUROCRINE BIOSCIENCES INC$89.5M2.16%$140.11$174.26+24.4%
2.2%
APGEAPOGEE THERAPEUTICS INC$82.9M2.00%$38.58$132.91+244.5%
2.0%
MDGLMADRIGAL PHARMACEUTICALS INC$74.1M1.79%$279.31$528.10+89.1%
1.8%
AORTARTIVION INC$71.7M1.73%$25.45$23.97-5.8%
1.7%
SYRESPYRE THERAPEUTICS INC$71.3M1.72%$24.55$86.63+252.9%
1.7%
CRNXCRINETICS PHARMACEUTICALS IN$66.1M1.59%$46.07$42.23-8.3%
1.6%
EOLSEVOLUS INC$62.4M1.50%$11.08$6.90-37.7%
1.5%
SWTXSPRINGWORKS THERAPEUTICS INC$62.3M1.50%β€”β€”
1.5%
CRGXCARGO THERAPEUTICS INC$60.5M1.46%β€”β€”
1.5%
ATXSASTRIA THERAPEUTICS INC$59.0M1.42%β€”β€”
1.4%
NTRANATERA INC$57.4M1.38%$107.81$279.32+159.1%
1.4%
VRCAVERRICA PHARMACEUTICALS INC$51.8M1.25%$79.50$6.14-92.3%
1.3%
BHVNBIOHAVEN LTD$51.5M1.24%$35.31$15.96-54.8%
1.2%
IMVTIMMUNOVANT INC$50.8M1.22%$27.51$38.79+41.0%
1.2%
MGTXMEIRAGTX HLDGS PLC$47.7M1.15%$4.10$13.92+239.5%
1.1%
PTGXPROTAGONIST THERAPEUTICS INC$44.0M1.06%$35.20$131.62+273.9%
1.1%
SLDBSOLID BIOSCIENCES INC$39.2M0.94%$6.27$10.84+72.9%
0.9%
CELCCELCUITY INC$38.7M0.93%$16.64$107.95+548.7%
0.9%
MDTMEDTRONIC PLC$38.6M0.93%$72.29$83.19+15.1%
0.9%
VKTXVIKING THERAPEUTICS INC$38.2M0.92%$55.32$37.44-32.3%
0.9%

Quarter-on-Quarter Activity

New Positions

None this quarter

Exited Positions

None this quarter

Increased

None this quarter

Trimmed

None this quarter

← Back to Hedge Funds
Perceptive Advisors Q2 2024 13F Filing β€” Holdings & Portfolio | MarketsFN